GlassScriptPhysician profile
William James Degan
NPI 1417336884
$3,497.62
in general payments reported to CMS, 2019-2025
28 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $139 · 2021: $246 · 2022: $374 · 2023: $867 · 2024: $993 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,970.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $570.49 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $512.16 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $350.58 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.24 | 2019-2024 | Jardiance |
| Gilead Sciences, INC. | $236.85 | 2023-2025 | Biktarvy |
| Glaxosmithkline, LLC. | $231.70 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $195.91 | 2019-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $168.37 | 2019-2024 | |
| Lilly USA, LLC | $154.05 | 2019-2024 | Zepbound |
| Exact Sciences Corporation | $135.71 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $84.85 | 2019-2020 | |
| Amarin Pharma, INC. | $59.59 | 2021 | |
| Abbott Laboratories | $50.08 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $48.30 | 2019-2020 | |
| Almatica Pharma LLC | $42.49 | 2023 | Gralise |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $38.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.03 | 2022-2023 | |
| Viiv Healthcare Company | $36.76 | 2024 | Apretude |
| Biohaven Pharmaceuticals, INC. | $33.55 | 2021 | |
| Vanda Pharmaceuticals INC. | $31.07 | 2019 | |
| Sanofi Pasteur INC. | $26.03 | 2019 | |
| Idorsia Pharmaceuticals US INC | $24.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.84 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2024 | |
| Dynavax Technologies Corporation | $19.62 | 2023 | Heplisav-B |
| Esperion Therapeutics, INC. | $18.78 | 2021 | |
| Nevro Corp. | $18.41 | 2023 | Senza |
| Ethicon US, LLC | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Degan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.